Announcement • Jun 25
AprilBio Co.,Ltd. announced that it expects to receive KRW 141.78468672 billion in funding from Imm Asset Management and other investors.
AprilBio Co.,Ltd. announced private placement to issue 4,095,456 common shares at an issue price of KRW 34,620 for gross proceeds of KRW 141,784,686,720 and 3,608,595 Registered Convertible Preferred Shares at an issue price of KRW 42,953 for gross proceeds of KRW 154,999,981,035 for total aggregate gross proceeds of KRW 296,784,667,755 on June 24, 2026. The transaction includes participation from Imm Asset Management for 2,023,998 common shares, IMM Scale-Up Bio No.1 Limited Company for 2,071,458 common shares, TKG Huchems Co., Ltd. for 3,492,189 preferred shares, IMM Startup Venture Fund No. 2 for 116,406 preferred shares. The preferred shares have a dividend rate of 1% per annum and are 100% convertible into 3,608,595 common shares at a conversion price of KRW 42,953 at a conversion period from July 24, 2027 to July 23, 2036. The common and preferred shares are restricted and will have a lock up period of 1 year. The company will raise funds by third party allotment. The transaction is approved by board of directors of the company and is expected to close on July 23, 2026. Total Shares Issued Before Capital Increase are 23,413,826 shares and post issuance the shares will be 27,509,282 shares.